MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

French biotech MaaT Phar­ma says its acute graft-ver­sus-host dis­ease treat­ment ex­ceed­ed ex­pec­ta­tions in a sin­gle-arm Phase 3 study in Eu­rope.

The com­pa­ny now in­tends to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER